One year in review 2015: Spondyloarthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue 6, 2015, Pages 769-778

  Giovannini, Leonardo ^a   Orlandi, Martina ^a   Lodato, Cristina ^b   Cioffi, Elisa ^b   Tenti, Sara ^c   Bardelli, Marco ^c   Talarico, Rosaria ^b   Guiducci, Serena ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Autoimmunity; DMARDs; Epidemiology pathogenesis; Spondyloarthritis

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

DISEASE MANAGEMENT; GENETIC ASSOCIATION; HUMAN; PATHOPHYSIOLOGY; SPONDYLARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISEASE MANAGEMENT; GENOME-WIDE ASSOCIATION STUDY; HUMANS; SPONDYLARTHRITIS;

EID: 84957938646     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. HAMILTON L, MACGREGOR A, WARMINGTON V, PINCH E, GAFFNEY K: The prevalence of inflammatory back pain in a UK primary care population. Rheumatology (Oxford) 2014; 53: 161-4.
2. CIUREA A, SCHERER A, WEBER U et al.: Age at symptom onset in ankylosing spondylitis: is there a gender difference? Ann Rheum Dis 2014; 73: 1908-10.
3. DEAN LE, JONES GT, MACDONALD AG, DOWNHAM C, STURROCK RD, MACFARLANE GJ: Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014; 53: 650-7.
4. STOLWIJK C, ESSERS I, VAN TUBERGEN A et al.: The epidemiology of extra-aticular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 2015; 74: 1373-8.
5. HENES JC, ZIUPA E, EISFELDER M et al: High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a crosssectional study. Rheumatol Int 2014; 34: 227-34.
6. LÖFVENDAHL S, THEANDER E, SVENSSON Å, CARLSSON KS, ENGLUND M, PETERSSON IF: Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden - a population-based register study. PLoS One 2014; 9: e98024.
7. FICCO HM et al: Prevalence of psoriasi arthritis in psoriasis patients according to newer classification criteria. Clin Rheuamtol 2014; 33: 1489-93.
8. QUEIRO R, TEJÓN P, ALONSO S, COTO P: Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford) 2014; 53: 1178-85.
9. ATZENI F, DEFENDENTI C, DITTO MC et al: Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 2014; 13: 20-3.
10. VAN PRAET L, JANS L, CARRON P et al: Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 2014; 73: 1186-9.
11. BOONEN A, SIEPER J, VAN DER HEIJDE D et al.: The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum 2015; 44: 556-62.
12. DING J, FENG Y, ZHENG ZH, LI XY, WU ZB, ZHU P: Increased expression of human leucocyte antigen class I free heavy chains on monocytes of patients with spondyloarthritis and cells transfected with HLA-B27. Int J Immunogenet 2015; 42: 4-10.
13. JEANTY C, SOURISCE A, NOTEUIL A et al: HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis. Arthritis Rheumatol 2014; 66: 2113-23.
14. CHEN L, FISCHER R, PENG Y et al: Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27. Arthritis Rheumatol 2014; 66: 284-94.
15. SANZ-BRAVO A, CAMPOS J, MAZARIEGOS MS, LÓPEZ DE CASTRO JA: Dominant role of the ERAP1 polymorphism R528K in shaping the HLA-B27 Peptidome through differential processing determined by multiple peptide residue. Arthritis Rheumatol 2015; 67: 692-701.
16. COSTANTINO F, TALPIN A, EVNOUCHIDOU I: ERAP1 gene expression is influenced by non-synonymous polymorphisms associated with predisposition to spondyloarthritis. Arthritis Rheumatol 2015; 67: 1525-34.
17. DARYABOR G, MAHMOUDI M, JAMSHIDI A et al.: Determination of IL-23 receptor gene polymorphism in Iranian patients with ankylosing spondylitis. Eur Cytokine Netw 2014; 25: 24-9.
18. EIRÍS N, GONZÁLEZ-LARA L, SANTOS-JUANES J, QUEIRO R, COTO E, COTO-SEGURA P: Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J Dermatol Sci 2014; 75: 167-72.
19. POPADIC S, RAMIC Z, MEDENICALJ, PRAVICA V, POPADIC D: IL-23R gene polymorphism rs2201841 is associated with psoriatic arthritis. Int J Immunogenet 2014; 41: 335-7.
20. KARADERI T, KEIDEL SM, POINTON JJ et al.: Ankylosing spondylitis is associated with the anthrax toxin receptor 2 gene (ANTXR2). Ann Rheum Dis 2014; 73: 2054-8.
21. LI X, WANG M, MA R et al.: Tumor necrosis factor receptor-II nt587 polymorphism in Chinese Han patients with ankylosing spondylitis. Genet Mol Res 2014; 7; 13: 5190-8.
22. WANG M, JI B, WANG J et al.: Tim-3 polymorphism downregulates gene expression and is involved in the susceptibility to ankylosing spondylitis. DNA Cell Biol 2014; 33: 723-8.
23. MA X, LIU Y, ZHANG H et al.: Evidence for genetic association of CARD9 and SNAPC4 with ankylosing spondylitis in a Chinese Han population. J Rheumatol 2014; 41: 318-24.
24. HUANG CH, WEI JC, CHEN CC et al: Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis. Rheumatol Int 2014; 34: 683-91.
25. LAI NS, CHOU JL, CHEN GC, LIU SQ, LU MC, CHAN MW: Association between cytokines and methylation of SOCS-1 in serum of patients with ankylosing spondylitis. Mol Biol Rep 2014; 41: 3773-80.
26. QIAN BP, WANG XQ, QIU Y, JIANG J, JI ML, FENG F: Association of receptor activator of nuclear factor-kappaB ligand (RANKL) gene polymorphisms with the susceptibility to ankylosing spondylitis: a case-control study. J Orthop Sci 2014; 19: 207-12.
27. ZHOU X, WANG J, ZOU H et al.: MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Ann Rheum Dis 2014; 73: 1552-7.
28. CHANDRAN V, BULL SB, PELLETT FJ, AYEARST R, POLLOCK RA, GLADMAN DD: Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology (Oxford) 2014; 5: 233-9.
29. MURDACA G, GULLI R, SPANÒ F et al.: TNF-a gene polymorphisms: association with disease susceptibility and response to anti-TNF-a treatment in psoriatic arthritis. J Invest Dermatol 2014; 134: 2503-9.
30. BAERLECKEN NT, NOTHDORFT S, STUMM-VOLL GH et al.: Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2014; 73: 1211-4.
31. BARALIAKOS X, BAERLECKEN N, WITTE T HELDMANN F, BRAUN J: High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 2014; 73: 1079-82.
32. TSUI FW, TSUI HW, LAS HERAS F, PRITZKER KP, INMAN RD: Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 2014; 73: 1873-9.
33. REHAUME LM, MONDOT S, AGUIRRE DE CARCER D et al.: ZAP-70 genotype disrupts the relationship between microbiota and host leading to spondyloarthritis and ileitis. Arthritis Rheumatol 2014; 66: 2780-92.
34. BENHAM H, REHAUME LM, HASNAIN SZ et al.: Interleukin-23 mediates the intestinal response to microbial ß-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014; 66: 1755-67.
35. KHMALADZEI A, KELKKA T, GUERARD S et al.: Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci USA 2014; 111: E3669-78.
36. HANSSON C, ERIKSSON C, ALENIUS GM: S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res 2014; 2014: 696-415.
37. OKTAYOGLU P, BOZKURT M, METE N, CAGLAYAN M, EM S, NAS K: Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Investig Med 2014; 62: 880-4.
38. JACQUES P, LAMBRECHT S, VERHEUGEN E et al.: Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014; 73: 437-45.
39. PACHECO-TENA C, PÉREZ-TAMAYO R, PINEDA C: Bone lineage proteins in the entheses of the midfoot in patients with spondyloarthritis. J Rheumatol 2015; 42: 630-7.
40. KLINGBERG E, NURKKALA M, CARLSTEN H, FORSBLAD-D'ELIA H: Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 2014; 41: 1349-56.
41. FAGERLI KM, VAN DER HEIJDE D, HEIBERG MS et al.: Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. Rheumatology (Oxford) 2014; 53: 1087-94.
42. BRAUN J, VAN DEN BERG R, BARALIAKOS X et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
43. FAGERLI KM, LIE E, VAN DER HEIJDE D, HEIBERG MS, LEXBERG AS, RODEVAND E: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014; 73: 132-7.
44. NIKIPHOROU E, NEGOESCU A, FITZPATRICK JD et al.: Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 2014; 33: 609-14.
45. ASIRI A, THAVANESWARAN A, KALMANLAMB G, CHANDRAN V, GLADMAN DD: The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol 2014; 32: 728-31.
46. COLOMBO D, CHIMENTI S, GROSSI P et al.: Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study. Biomed Res Int 2014; 2014: 9417-67.
47. VAN DER HEIJDE D, SIEPER J et al.: ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 7: 905-8.
48. PEDERSEN SJ, WICHUK S, CHIOWCHAN-WISAWAKIT P, LAMBERT RG, MAKSYMOWYCH WP: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis. Arthritis Res Ther 2014; 22; 16: R100.
49. MOLTÓ A, PATERNOTTE S, CLAUDEPIERRE P, BREBAN M, DOUGADOS M: Effectiveness of tumor necrosis factor a blockers in early axial spondyloarthritis: data from the DESIR cohort. Arthritis Rheumatol 2014; 66: 1734-44.
50. EDER L, THAVANESWARAN A, CHANDRAN V, GLADMAN DD: Tumour necrosis factor a blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis 2014; 73: 1007-11.
51. PRINCE DS, McGUIGAN LE, McGIRR EE: Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis 2014; 17: 165-72.
52. ALMIRALL M, LÓPEZ-VELANDIA JG, MAYMÓ J: Absence of radiographic progression at two years in a cohort of patients with non-radiographic axial spondyloarthritis treated with TNF-a blockers. Reumatol Clin 2014; 10: 134-5.
53. GULFE A, KAPETANOVIC MC, KRISTENSEN LE: Efficacy and drug survival of antitumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scand J Rheumatol 2014; 43: 493-7.
54. GULYAS K, BODNAR N, NAGY Z et al: Reallife experience with switching TNF-a inhibitors in ankylosing spondylitis. Eur J Health Econ 2014; 15 (Suppl. 1): S93-100.
55. JANI M, MACPHIE E, RAO C et al.: Effectiveness of switching between biologics in psoriatic arthritis-results of a large regional survey. Clin Med 2014; 14: 95-6.
56. GERMANO V, CATTARUZZA MS, OSBORN J et al.: Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-a antagonists. J Transl Med 2014; 12: 77.
57. WALLIS D, THAVANESWARAN A, HAROON N, AYEARST R, INMAN RD: Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology (Oxford) 2015; 54: 152-6.
58. KIM YJ, KIM YG, SHIM TS et al.: Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford) 2014; 53: 1477-81.
59. SUH YS, KWOK SK, JU JH, PARK KS, PARK SH, YOON CH: Safe re-administration of tumor necrosis factor-alpha (TNF-a) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNF-a therapy. J Korean Med Sci 2014; 29: 38-42.
60. COSTA L, CASO F, ATTENO M et al.: Longterm safety of anti-TNF-a in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014; 33: 273-6.
61. WESTHOVENS I, LORIES RJ, WESTHOVENS R, VERSCHUEREN P, DE VLAM K: Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clin Exp Rheumatol 2014; 32: 71-6.
62. HELLGREN K, SMEDBY KE, BACKLIN C et al.: Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 2014; 66: 1282-90.
63. GLINTBORG B, GUDBJORNSSON B, KROGH NS et al.: Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology (Oxford). 2014; 53: 2100-9.
64. SIEPER J, LENAERTS J, WOLLENHAUPT J et al.: Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study. Ann Rheum Dis 2014; 73: 101-7.
65. DE STEFANO R, FRATI E, DE QUATTRO D, MENZA L, MANGANELLI S: Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 2014; 33: 707-11.
66. DOUGADOS M, WOOD E, COMBE B et al.: Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebocontrolled SPARSE study. Arthritis Res Ther 2014; 16: 481.
67. SONG IH, HERMANN KG, HAIBEL H et al.: Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. Rheumatology (Oxford) 2015; 54: 257-61.
68. DOUGADOS M, VAN DER HEIJDE D, SIEPER J et al.: Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66: 2091-102.
69. HUANG F, GU J, ZHU P et al.: Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 2014; 73: 587-94.
70. VOGELZANG EH, KNEEPKENS EL, NURMOHAMED MT et al.: Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 2014; 73: 2178-82.